

STRIDES PHARMA CANADA INC.
BALANCE SHEET AS AT MARCH 31, 2023

	Note No.	Amount in CAD 31-Mar-23	Amount in CAD 31-Mar-22
A ASSETS			
I Non-current assets			
(a) Property, plant and equipment		854,875	1,092,335
(b) Intangibles assets under development		1,582,183	1,482,139
(c) Financial assets			
(i) Investments	1	3,803,195	3,803,195
Total non-current assets		6,240,253	6,377,669
I Current assets			
(a) Inventories		172,061	869,314
(a) Financial assets			
(i) Trade receivables	2	462,456	305,256
(ii) Cash and cash equivalents	3	45,990	169,188
(b) Other current assets	4	2,969,705	86,883
Total current assets		3,650,212	1,430,641
TOTAL ASSETS		9,890,465	7,808,310
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	5	1,000	1,000
(b) Other equity	6	7,017,380	6,410,206
Total Equity		7,018,380	6,411,206
II Liabilities			
1 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	7	309,046	170,597
(ii) Other financial liabilities	8	2,172,895	1,032,559
(b) Provisions	9	390,144	193,948
Total current liabilities		2,872,085	1,397,104
TOTAL EQUITY AND LIABILITIES		9,890,465	7,808,310

STRIDES PHARMA CANADA INC.
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2023

		Amount in CAD	Amount in CAD
Particulars	Note No.	31-Mar-23	31-Mar-22
1 Revenue from operations	10	867,679	2,097,112
2 Other Income	11	49,893	74,628
3 Total Revenue (1+2)		917,572	2,171,739
4 Expenses			
(a) Cost of goods sold		1,321,374	350,755
(b) Employee benefits expense	12	66,521	371,343
(c) Finance costs	13	3,436	4,046
(d) Depreciation and amortisation expense		237,460	126,527
(e) Other expenses	14	796,608	986,029
Total expenses		2,425,398	1,838,700
5 Profit / (Loss) before exceptional items and taxes (3-4)		(1,507,826)	333,039
6 Exceptional Item		-	-
7 Profit / (Loss) before taxes (5+6)		(1,507,826)	333,039
8 Tax Expense:			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
9 Profit / (Loss) for the year after tax		(1,507,826)	333,039

STRIDES PHARMA CANADA INC.
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED MARCH 31, 2023

(A) Equity share capital

Particulars	Amount in CAD
Balance as at March 31, 2022	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2023	1,000

(B) Other equity

Amount in CAD

Particulars	Share application money pending allotment	Reserves and surplus	Total
		Retained earnings	
Balance as at March 31, 2022	7,839,265	(1,429,059)	6,410,206
Application money received during the year	2,115,000	-	2,115,000
Profit/loss for the year	-	(1,507,826)	(1,507,826)
Balance as at March 31, 2023	9,954,265	(2,936,885)	7,017,380

STRIDES PHARMA CANADA INC.

Notes forming part of financial statement

Note

No.

1	Non current investments	Amount in CAD	
	Particulars	31-Mar-23	31-Mar-22
	Pharmapar Inc	3,803,195	3,803,195
	Total	3,803,195	3,803,195
2	Trade receivables	Amount in CAD	
	Particulars	31-Mar-23	31-Mar-22
	Unsecured		
	Considered good	462,456	305,256
	Total	462,456	305,256
3	Cash and cash equivalents	Amount in CAD	
	Particulars	31-Mar-23	31-Mar-22
	Cash in hand		
	Balances with banks:		
	In current accounts	45,990	169,188
	Total	45,990	169,188
4	Other current assets	Amount in CAD	
	Particulars	31-Mar-23	31-Mar-22
	Unsecured, considered good		
	Loans and advances to Group entities	2,881,716	-
	Balances with government authorities		
	- GST receivable	86,788	
	Prepaid Expenses	1,201	86,883
	Total	2,969,705	86,883
5	Share capital	Amount in CAD	
	Particulars	31-Mar-23	31-Mar-22
	Issued, subscribed and fully paid-up		
	Equity share capital	1,000	1,000
	Total	1,000	1,000
6	Reserves and surplus	Amount in CAD	
	Particulars	31-Mar-23	31-Mar-22
	Share Application money Pending Allotment	7,839,265	7,839,265
	Add: Additions during the year	2,115,000	-
	Closing balance	9,954,265	7,839,265
	Surplus in statement of profit and loss		
	Opening balance	(1,429,059)	(1,501,124)
	Add: Profit / (Loss) for the year	(1,507,826)	72,065
	Closing balance	(2,936,885)	(1,429,059)
	Total	7,017,380	6,410,206

STRIDES PHARMA CANADA INC.

Notes forming part of financial statement

7 Trade payables Amount in CAD

Particulars	31-Mar-23	31-Mar-22
Trade payable	309,046	170,597
Total	309,046	170,597

8 Other Current financial Liabilities Amount in CAD

Particulars	31-Mar-23	31-Mar-22
Payable to group entities	2,177,205	980,069
Other payables:		
- Statutory remittances	(4,310)	52,491
Total	2,172,895	1,032,559

9 Provisions Amount in CAD

Particulars	31-Mar-23	31-Mar-22
Provision for expenses	390,144	193,948
Total	390,144	193,948

STRIDES PHARMA CANADA INC.
Notes forming part of financial statement

Note

No.

10 Revenue from operations **Amount in CAD**

Particulars	31-Mar-23	31-Mar-22
Sale of Product	867,679	2,097,112
Total	867,679	2,097,112

11 Other Income **Amount in CAD**

Particulars	31-Mar-23	31-Mar-22
Other Income	-	15,944
Sundry balance written back	9	-
Interest Income	49,883	58,684
Total	49,893	74,628

12 Employee Benefit Expenses **Amount in CAD**

Particulars	31-Mar-23	31-Mar-22
Salaries and wages	66,521	371,343
Total	66,521	371,343

13 Finance cost **Amount in CAD**

Particulars	31-Mar-23	31-Mar-22
Finance Cost	3,436	4,046
Total	3,436	4,046

14 Other expenses **Amount in CAD**

Particulars	31-Mar-23	31-Mar-22
Freight and forwarding	89,297	41,903
Coverion & processing charges	110,000	156,847
Consumables	20,692	44,238
Director sitting fees	7,000	-
Commission	32	2,615
General Expenses	7,306	-
Rates & Taxes	221,675	101,207
Repairs & Maintenance	4,811	7,239
Insurance	1,205	3,843
Conveyance & Travelling	340	554
Advertising & selling expenses	5,175	54,912
Net loss on foreign currency transactions	62,275	43,074
Professional fees	246,453	279,217
Miscellaneous Expense	20,347	250,379
Total	796,608	986,029